NASDAQ$ESTA

Establishment Labs Holdings Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Reported record second quarter financial results with revenue increase and ongoing strategic initiatives.

Establishment Labs reported a record second quarter with a revenue of $48.6 million, an 18% increase year-over-year. The company is progressing with its U.S. PMA approval and commercialization preparations, alongside the global roll-out of Mia Femtech. A new Sulàyöm Innovation Campus was opened to expand manufacturing capacity and R&D capabilities.

  • Second quarter worldwide revenue reached a record $48.6 million, up 18.0% year-over-year.
  • 2023 revenue guidance remains between $200 million and $210 million, representing a 24% to 30% increase over 2022.
  • Second quarter loss from operations was $13.7 million, compared to $10.4 million in the year-ago period.
  • Cash balance totaled $90.2 million as of June 30, 2023.

Headline financials

Total Revenue

$48.6M

Previous: $41.2M+17.9%
EPS (adj)

-$0.65

Previous: -$1.52+57.2%
Capital Expenditures

-$3.55M

Previous: -$1.41M-152.6%
Free Cash Flow

-$20.3M

Previous: -$38.5M+47.3%
Net Income

-$16.7M

Previous: -$37.1M+54.9%
Operating Income

-$13.7M

Previous: -$10.4M-31.8%
Gross Profit

$30.3M

Previous: $27.5M+10.2%
Cash & Equivalents

$90.2M

Previous: $91.3M-1.2%
Total Assets

$285M

Previous: $200M+42.7%
Stock-Based Comp

$3.62M

Previous: $3.74M-3.4%

Revenue & EPS history

Establishment Labs · Revenue · Quarterly

$48.6M

Q2 2023+17.9%vs Q2 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

Establishment Labs anticipates a strong finish to the year, driven by the global roll-out of Mia Femtech and the pending approval of Motiva in China. The company's U.S. PMA is progressing through the approval process, and preparations for commercialization are underway.

Tailwinds

  • Ongoing global roll-out of Mia Femtech
  • Pending approval of Motiva in China
  • U.S. PMA progressing through the approval process
  • Preparations for commercialization continue in earnest
  • Fourteen Mia clinic partners established

Headwinds

  • Not mentioned

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

+1.5%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+2.4%

Avg return

30 days after

56%

18 / 32 earnings

Positive

+22.5%

Q3 2025

Best reaction

-26.0%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.4%-4.3%+2.9%
Q4 2025-1.9%+5.0%-20.1%
Q3 2025+22.5%+37.0%+43.2%
Q1 2025+4.9%+5.1%+14.2%
Q4 2024+17.9%+28.1%+12.1%
Q3 2024-5.2%-13.2%-10.0%
Q2 2024+3.4%+20.6%+23.5%
Q1 2024+5.4%+4.2%-10.8%
Q4 2023+15.1%+19.6%+28.2%
Q3 2023-26.0%-36.1%-31.7%
Q2 2023-8.4%-12.0%-12.2%
Q1 2023+1.8%-1.6%-1.9%
Q4 2022+7.2%+10.3%+0.3%
Q3 2022-7.7%+11.1%+27.1%
Q2 2022-3.0%+1.3%-0.4%
Q1 2022-10.5%-10.1%+2.3%
Q4 2021+3.3%+1.6%+11.5%
Q3 2021-10.6%-14.3%-15.2%
Q2 2021+6.0%-3.7%-3.1%
Q1 2021-0.6%-1.8%+8.9%
Q4 2020+0.4%-6.8%+9.5%
Q3 2020+8.9%-0.4%+22.6%
Q2 2020+6.2%+7.3%+9.3%
Q1 2020+2.9%+0.5%+15.3%
Q4 2019+4.5%-16.4%+0.4%
Q3 2019-0.3%+0.5%+7.8%
Q2 2019-5.2%-10.6%-10.2%
Q1 2019+1.5%-0.3%-15.9%
Q4 2018-1.9%-4.9%-15.2%
Q3 2017+10.3%+4.5%-6.2%
Q3 2018+10.3%+4.5%-6.2%
Q2 2018-2.7%-2.9%-3.4%
Q4 2017
Q2 2017
Q1 2017

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro